# MASSPAT VISANO OPIOID STEWARDSHIP PLATFORM – OVERVIEW GUIDE

Massachusetts Prescription Monitoring Program (PMP)

Massachusetts Department of Public Health
www.mass.gov/prescription-monitoring-program-pmp

# Contents

Introducing Visano ..... 3
Why Visano? ..... 3
How does Visano work? ..... 3
Who will have access to the Visano pilot? ..... 3
Visano Layout ..... 4
CS Insights Report ..... 5
Patient Demographic ..... 5
Risk Indicators ..... 6
Graphs ..... 7
Summary and Rx Data ..... 9
Resources ..... 10
Access to Treatment ..... 10
Educational Resources ..... 11

# Introducing Visano

The Massachusetts Department of Health is pleased to announce an upcoming enhancement to the Massachusetts Prescription Awareness Tool (MassPAT).

**On December 9, 2019**, all approved MassPAT users will have access to an advanced patient support tool called the Visano Opioid Stewardship Platform (Visano). In addition to the existing MassPAT functionality and the current patient PMP report, Visano will also offer a representation of the data in an interactive format to help physicians, pharmacists and care teams access and more quickly and easily comprehend the data to aid in clinical decisions and provide improved patient safety and outcomes. Visano also provides tools and resources that support patients' needs and connects them to treatment, when appropriate.

With this enhancement, healthcare providers will have access to all of the features and functions of Visano with a consistent look and feel for users who access the solution through the MassPAT web portal. It also enables delivery of Visano within Electronic Health Record (EHR) and Pharmacy Management Systems for those prescribers and dispensers in MA who choose to access Visano through integration within their healthcare IT system.

**This guide is intended to provide an overview of the Visano platform that provides a breakdown of each section of the report. In addition to this guide, a brief video overview of Visano can be found here.**

## Why Visano?

Visano is a platform to help clinicians identify, prevent and manage substance use disorder (SUD). We know that safe prescribing practices must be part of a multi-dimensional response to this public health crisis. It allows prescribers and dispensers to identify patients that may be at risk for prescription drug addiction, and resources that clinicians can utilize to ensure that patients can be provided with the care they need. The Visano platform is user friendly, faster, easily integrated into a patient's electronic medical record and it's interoperable with other states. We view Visano as an important component in our response to the current opioid crisis.

## How does Visano work?

Visano aggregates historical and active prescription data and presents color coded, interactive, visual representations of the data. In addition, the Visano report has a resource tab that includes a Medical Assistance Treatment (MAT) locator, CDC educational resources, and Massachusetts resources, including an opportunity for consultation through the Massachusetts Consultation Service for Treatment of Addiction and Pain (MCSTAP). These resources can be used to help patients in need, at the right time, in a meaningful way, quickly and easily, at the point of care.

## Who will have access to the Visano pilot?

Visano would be available to the MassPAT end user whether accessing via the MassPAT web portal or integrated EHR system or pharmacy software.

## Visano Layout

Visano is broken out into two separate tabs: CS Insights Report and Resources. CS Insights Report is the default presentation view and is powered by the same PMP data found on our standard report. The Resources tab takes you to a page with MAT, CDC, and Massachusetts resources that can be used for patient care.




Visano helps providers make better-informed decisions when it comes to identifying, preventing, and managing substance use disorders. An overview of each section can be found below.

# CS Insights Report




The CS Insights Report tab is broken into 5 sub-headers:

- Patient Demographic
- Risk Indicators
- Graphs
- Summary
- Rx Data

## Patient Demographic




The Patient Demographic sub-header contains all of the applicable linked records for the patient and the patient search criteria used to create the report. It will also display all known patient names, birthdates, and addresses that have been matched to the patient the user searched.

## Risk Indicators




Risk indicators, when applicable for a patient, will be displayed here. When collapsed a summary of how many Additional Risk Indicators (ARIs) will be displayed and expanding this will provide further detail. ARIs within PMP data have been shown to be predictors of adverse outcome, specifically unintentional overdose death. There are currently three PMP based additional risk indicators:

- More than 5 providers in any year (365 days)
- More than 4 pharmacies in any 90-day period
- More than 40 morphine milligram equivalent per day (40 MED) average and more than 100 MME total

A brief explanation of each indicator as well as clinical guidance is available by following the "Explanation and Guidance" link.

## Graphs




*Per CDC guidance, the MME conversion factors prescribed or provided as part of the medication-assisted treatment for opioid use disorder should not be used to benchmark against dosage thresholds meant for opioids prescribed for pain. Buprenorphine products have no agreed upon morphine equivalency, and as partial opioid agonists, are not expected to be associated with overdose risk in the same dose-dependent manner as doses for full agonist opioids. MME = morphine milligram equivalents. LME = Lorazepam milligram equivalents. mg = dose in milligrams.

The Graphs section is a key feature of the Visano platform that provides a visual and interactive representation of the PMP data for a particular patient. Users can easily visualize and understand patterns in prescribing and usage behaviors, as well as identify overlapping prescriptions.
Providers are listed on the left, and color-coded prescriptions are graphed in reverse time order. Clicking on any of the color shaded areas will provide information on the prescriptions that comprise that time period while clicking on any of the prescribers on the left-hand side will give prescriber details including address information.

Morphine Milligram Equivalent (MME) and Lorazepam Milligram Equivalent (LME) graphs can be found towards the bottom and the amounts for each will vary in accordance with the calculated amount for that time period. Information about the LME can be found under the Menu bar at the top of the report.

At the top of the Graphs section are checkboxes that provide the ability to filter by the prescription types of Narcotic, Sedative, Stimulant, or Other. Unchecking the Sedative data removes the LME chart while unchecking the Narcotic data removes the MME chart.




Users can select individual data points or hold and drag their mouse around an area on the graph to see details about the prescriptions in that time period:



## Summary and Rx Data



Summary

**Summary**

| | |
|---|---|
| Total Prescriptions: | 57 |
| Total Prescribers: | 14 |
| Total Pharmacies: | 16 |

**Narcotics*** (excluding buprenorphine)

| | |
|---|---|
| Current Qty: | 100 |
| Current MME/day: | 20.00 |
| 30 Day Avg MME/day: | 25.33 |

**Sedatives***

| | |
|---|---|
| Current Qty: | 94 |
| Current LME/day: | 11.00 |
| 30 Day Avg LME/day: | 9.37 |

**Buprenorphine***

| | |
|---|---|
| Current Qty: | 0 |
| Current mg/day: | 0.00 |
| 30 Day Avg mg/day: | 0.00 |

Rx Data

**PRESCRIPTIONS**

Total Prescriptions: 57
Total Private Pay: 29

| Fill Date | ID | Written | Drug | Qty | Days | Prescriber | Rx # | Pharmacy | Refill | Daily Dose * | Pymt Type | PMP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10/25/2019 | 2 | 10/25/2019 | Clonazepam 0.5 Mg Tablet | 90.00 | 30 | Be Doc | 1068176 | Dru (7569) | 1 | 3.00 LME | Comm Ins | KS |
| 10/10/2019 | 3 | 10/10/2019 | Alprazolam 1 Mg Tablet | 120.00 | 30 | | 04077535 | (4565) | 0 | 8.00 LME | Private Pay | KS |
| 09/30/2019 | 2 | 09/30/2019 | Clonazepam 0.5 Mg Tablet | 90.00 | 30 | Be Doc | 1068176 | Dru (7569) | 0 | 3.00 LME | Comm Ins | KS |
| 09/23/2019 | 2 | 09/23/2019 | Hydrocodon-Acetaminophn 10-325 | 180.00 | 90 | Bi Hea | 333217... | Rea (7994) | 0 | 20.00 MME | Comm Ins | KS |
| 09/16/2019 | 3 | 09/16/2019 | Alprazolam 1 Mg Tablet | 120.00 | 30 | | 04076995 | (4565) | 0 | 8.00 LME | Private Pay | KS |
| 09/10/2019 | 2 | 09/10/2019 | Alprazolam 1 Mg Tablet | 120.00 | 30 | Jo Pil | 358797 | Fak (5778) | 0 | 8.00 LME | Comm Ins | KS |
| 07/15/2019 | 9 | 07/15/2019 | Oxycontin 20 Mg Tablet | 60.00 | 60 | | 05077535 | Rea (4563) | 0 | 30.00 MME | Private Pay | MA |
| 07/17/2019 | 6 | 07/16/2019 | Alprazolam 1 Mg Tablet | 120.00 | 30 | | 04077535 | (4565) | 0 | 8.00 LME | Private Pay | MA |
| 07/16/2019 | 4 | 07/15/2019 | Oxycodone-Acetaminophen 5-325 | 10.00 | 10 | Ba Doc | 01042018 | Fak (5326) | 2 | 7.50 MME | Other | MA |
| 07/15/2019 | 9 | 07/12/2019 | Ambien Cr 12.5 Mg Tablet | 12.00 | 2 | Do Chi | 00655037 | Scr (4567) | 0 | 3.75 LME | Private Pay | MA |
| 07/15/2019 | 8 | 07/12/2019 | Oxycodone-Acetaminophen 5-325 | 60.00 | 30 | Ce Fam | 11767680 | We (4568) | 0 | 15.00 MME | Private Pay | MA |
| 07/15/2019 | 8 | 07/12/2019 | Alprazolam 1 Mg Tablet | 60.00 | 30 | Ce Fam | 11767692 | We (4568) | 0 | 4.00 LME | Private Pay | MA |
| 07/15/2019 | 3 | 07/15/2019 | Oxycodone Hcl 5 Mg Tablet | 60.00 | 30 | | 05077535 | Rea (4563) | 0 | 15.00 MME | Private Pay | KS |
| 07/14/2019 | 8 | 07/13/2019 | Percocet 5-325 Mg Tablet | 180.00 | 60 | Bi Hea | 333277... | Rea (4563) | 0 | 22.50 MME | Medicaid | MA |
| 07/14/2019 | 8 | 07/12/2019 | Percocet 5-325 Mg Tablet | 15.00 | 15 | Bi Hea | 333241... | Rea (4563) | 0 | 7.50 MME | Medicaid | MA |
| 07/13/2019 | 9 | 07/11/2019 | Clonazepam 0.5 Mg Tablet | 90.00 | 30 | Ba Doc | 00655736 | Dru (4566) | 0 | 3.00 LME | Private Pay | MA |
| 07/13/2019 | 8 | 07/11/2019 | Hydrocodon-Acetaminophen 5-325 | 120.00 | 30 | Ce Fam | 111788... | We (4568) | 0 | 20.00 MME | Private Pay | MA |
| 07/12/2019 | 8 | 07/06/2019 | Carisoprodol 350 Mg Tablet | 30.00 | 15 | Fa Hos | 505670 | Fak (4561) | 1 | 0.56 LME | Private Pay | MA |
| 07/12/2019 | 8 | 07/11/2019 | Hydrocodon-Acetaminophn 10-325 | 180.00 | 90 | Bi Hea | 333217... | Rea (4563) | 0 | 20.00 MME | Medicaid | MA |
| 07/12/2019 | 8 | 07/06/2019 | Alprazolam 1 Mg Tablet | 60.00 | 30 | Ce Fam | 111796... | We (4568) | 0 | 4.00 LME | Private Pay | MA |
| 07/12/2019 | 9 | 07/13/2019 | Oxycodone Hcl 5 Mg Tablet | 60.00 | 30 | | 05077535 | Rea (4563) | 0 | 15.00 MME | Private Pay | MA |

*Per CDC guidance, the MME conversion factors prescribed or provided as part of the medication-assisted treatment for opioid use disorder should not be used to benchmark against dosage thresholds meant for opioids prescribed for pain. Buprenorphine products have no agreed upon morphine equivalency, and as partial opioid agonists, are not expected to be associated with overdose risk in the same dose-dependent manner as doses for full agonist opioids. MME = morphine milligram equivalents. LME = Lorazepam milligram equivalents. mg = dose in milligrams.

**Providers**

Total Providers: 14

| Name | Address | City | State | Zipcode | Phone |
|---|---|---|---|---|---|
| Tony Stark | 123 Fake Street | Boston | MA | 02122 | - |
| Candice Familydoc | | | | | - |

**Pharmacies**

Total Pharmacies: 16

| Name | Address | City | State | Zipcode | Phone |
|---|---|---|---|---|---|
| Fake Pharm (5326) | 123 Fake St | Boston | MA | 02115 | (617) 555-5555 |
| Real Chain Store 2 (3750) | 987 Orange Rd | Grove City | OH | 43123 | - |

At the end of the report you'll find the prescription data that makes up the Visano report. This is the same information available on the classic MassPAT report and is provided by pharmacies on a daily basis via the PMP Clearinghouse.

# Resources

MAT, MA pain management and SUD resources, and CDC Resources are accessible from the header by clicking on the Resources tab.




## Access to Treatment




The Access to Treatment sub-header allows users to Medication-Assisted Treatment (MAT) providers for this patient. Entering the patient's zip code, which is pre-populated if available, and clicking Submit will provide the 30 closest MAT providers:

**Buprenorphine Treatment Physician Locator - Nearest 30 Providers Around 02114**

This resource is based on publicly available data from the Substance Abuse and Mental Health Services Administration (SAMHSA). The content provided is updated quarterly. More information is available at http://www.samhsa.gov/medication-assisted-treatment/physician-program-data/treatment-physician-locator

| Name | Address | City | State | Zip | Phone | Distance |
|---|---|---|---|---|---|---|
| Dr. Gregory Acampora M.D. | Massachusetts General HospitalCenter for Addiction Medicine | Boston | Massachusetts | 02114 | (617) 643-5026 | 0.0 miles |
| Richard Ahern NP | 55 Fruit StreetGRJ 504 | Boston | Massachusetts | 02114 | (617) 724-5158 | 0.0 miles |
| John Albin MD | 55 Fruit StreetCox 5 | Boston | Massachusetts | 02114 | (617) 726-3906 | 0.0 miles |
| Jonathan Alpert | Massachusetts General Hospital15 Parkman Street | Boston | Massachusetts | 02114 | (617) 726-5948 | 0.0 miles |
| James Baker | Yawkey Center for Outpatient Care 3E139A Charles Street, Suite 239 | Boston | Massachusetts | 02114 | (508) 769-3426 | 0.0 miles |
| Dr. Joshua Barocas MD | 55 Fruit Street | Boston | Massachusetts | 02114 | (314) 349-3278 | 0.0 miles |
| Pierre Borczuk MD | Massachusetts General HospitalZero Emerson Place Suite 3b | Boston | Massachusetts | 02114 | (617) 726-7622 | 0.0 miles |

This data is provided by the Substance Abuse and Mental Health Services Administration (SAMHSA). View more information about the treatment locator, here.

## Educational Resources




To assist providers in educating their patients, printable CDC pamphlets are also available. In addition to CDC provided resources Massachusetts specific resources, in coordination with the Bureau of Substance Addiction Services (BSAS) and Massachusetts Consultation Services for Treatment of Addiction and Pain (MCSTAP), will also be available. More information about the CDC resources can be found here.